Wells Fargo & Company Aridis Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$0.16 - $0.4 $16 - $42	105 Added 7.75%	1,459 $0
Q1 2023 May 12, 2023	SELL	$0.31 - $1.5 $7 - $36	-24 Reduced 1.74%	1,354 $0
Q4 2022 Feb 13, 2023	BUY	$0.81 - $1.18 $38 - $55	47 Added 3.53%	1,378 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.73 - $2.47 $13 - $44	18 Added 1.37%	1,331 $1,000
Q2 2022 Aug 12, 2022	BUY	$0.91 - $1.7 $27 - $51	30 Added 2.34%	1,313 $1,000
Q1 2022 May 16, 2022	SELL	$1.33 - $2.59 $14 - $28	-11 Reduced 0.85%	1,283 $3,000
Q4 2021 Feb 14, 2022	BUY	$2.0 - $3.65 $46 - $83	23 Added 1.81%	1,294 $3,000
Q2 2021 Aug 16, 2021	BUY	$5.3 - $7.4 $26 - $37	5 Added 0.39%	1,271 $9,000
Q1 2021 May 13, 2021	BUY	$5.54 - $8.1 $5,124 - $7,492	925 Added 271.26%	1,266 $7,000
Q4 2020 Feb 09, 2021	BUY	$6.07 - $8.01 $54 - $72	9 Added 2.71%	341 $2,000
Q3 2020 Nov 05, 2020	SELL	$6.33 - $7.75 $37 - $46	-6 Reduced 1.78%	332 $2,000
Q1 2020 May 14, 2020	BUY	$4.34 - $8.3 $1,466 - $2,805	338 New	338 $2,000

50.2K

Ticker ARDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,701,600
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.